Comments
Ranbaxy Laboratories reported a fourth-quarter loss as operating expenses rose from a year earlier.
The company, controlled by Japan's Daiichi Sankyo, only reported full-year results and declined to comment on what caused the loss.
Calculation showed that the net loss during October-December was Rs 111 crore compared with a profit of Rs 262 crore during the corresponding quarter a year earlier.
Ranbaxy had declared profit of Rs 1,607 crore for the nine-month period in 2010 and Rs 1,496 crore for the entire year.
Asked why the company had not reported Q4 numbers for 2010, a company spokesperson said that according to SEBI norms it is allowed to declare the results for the entire year.
Ranbaxy's share price was down 3 per cent to Rs 494 on the Bombay Stock Exchange at close on Tuesday.
For the entire year ended December 31, the pharmaceutical company posted a five-fold rise in net profit to Rs 1,496 crore compared with Rs 296 crore reported a year earlier.
Global sales for the full year were at Rs 8,550 crore against Rs 7,344 crore last year. The board of directors of the company recommended a dividend of Rs 2 a share. For 2011, the company said it expects to achieve base case sales of approximately Rs 8,400 crore.
Base case sales exclude revenue from the possibility of exclusive sales Ranbaxy could get for being the first to bring a generic drug to market. Commenting on the results for the year, Mr Arun Sawhney, Managing Director, Ranbaxy, said: “We have had a strong year attributable to the robust revenue growth in our key geographies and the realisations from our First-to-File opportunities in the US. On the cost side, we have gained from greater efficiencies in manufacturing.”
Despite facing regulatory challenges in the US, the company posted a 80 per cent growth in sales to Rs 2,744 crore in 2010.
The India business recorded sales of Rs 17,59 crore a growth of 8 per cent over the previous year.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.